Novozymes is a global biotechnology company headquartered in Bagsværd outside of Copenhagen, Denmark employing approximately 6,300 people by the end of 2013. The company has operations in a number of countries around the world, including China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Its B shares are listed on the NASDAQ OMX Nordic.The company’s focus is the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. As of 2013, the company holds an estimated 48% of the global enzyme market, making it the world’s largest producer of industrial enzymes. Wikipedia.
Novozymes AS | Date: 2017-03-08
The present invention relates to a method for producing a dairy product using an enzyme having lactase activity. Particular embodiments include a method for producing a fermented dairy product comprisinga) providing a milk-based substrate comprising lactose,b) treating said substrate with an enzyme having lactase activity, where the pH optimum of the lactase activity at 37C is above pH 5, and where the lactase activity of the enzyme at pH 5 is at least 50% of its lactase activity at pH 6 when measured at 37C, andc) fermenting said substrate with a microorganism. Also included is a method wherein the enzyme having lactase activity has an amino acid sequence which is at least 70% identical to amino acids 28-1331 of SEQ ID NO: 2. Also included is a method wherein the enzyme having lactase activity has an amino acid sequence which is at least 70% identical to amino acids 28-1931 of SEQ ID NO: 1 or a fragment thereof. Also included is a method wherein the enzyme having lactase activity is derived from a microorganism of the genus Bifidobacterium.
Novozymes AS | Date: 2017-02-01
Compositions and methods for enhancing plant growth and crop yield in legumes and non-legumes are described. The compositions include lipo-chitooligosaccharides in combination with flavonoid compounds, especially genistein or daidzein. The method includes applying the compositions to seeds and/or plants either concomitantly or sequentially.
Novozymes AS | Date: 2017-01-25
The present invention relates to a method of enhancing growth conditions for plants by growing the plants in soil containing, in proximity to the plant roots, both a phosphorus source and at least two different strains of Penicillium selected from the group consisting of ATCC 18309, ATCC 20851, ATCC 22348, NRRL 50162, NRRL 50169 and NRRL 50170.
Novozymes AS | Date: 2017-03-15
The present invention relates to methods for degrading or converting a cellulosic material, methods for producing a fermentation product, and methods of fermenting a cellulosic material with an enzyme composition comprising one or more (several) cellulolytic enzymes, a cellobiose dehydrogenase, and a polypeptide having cellulolytic enhancing activity.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: BIOTEC-6-2015 | Award Amount: 8.81M | Year: 2016
Metagenomes comprise enormous reservoirs coding for proteins with useful activities. Unfortunately, harvesting this reservoir is difficult, because useful candidates are rare and hidden in an overwhelming majority of irrelevant genes. Screening campaigns of metagenomic libraries thus require massive capital-expenditure for robotic systems and much manpower, making them expensive, slow and available to very few users. To enable valorisation of the potential of the metagenome, this project assembles an interdisciplinary and intersectoral consortium that will integrate a range of technologies into a platform designed to beat the odds of identifying library hits faster, more efficiently and by a wider user base. Exploration and exploitation of the metagenome will be made faster and more successful by (i) ultrahigh-throughput screening in picoliter droplets that dramatically lowers the cost per assay to well below 0.01 cents and allows throughput of 10e7 assays per hour; (ii) workflows that streamline and increase the yield of library construction and functional expression and (iii) workflows for efficient bioinformatic analysis of hits based on user-friendly software solutions for metagenome analysis. Emphasis is put on technologies that are straightforwardly implemented in non-specialist labs, maximising the impact of METAFLUIDICS. This platform will be used to identify enzymes for biosynthesis of therapeutic small molecules, for green bioenergy conversion, bioremediation, food chemistry and other industrial applications
Agency: Cordis | Branch: H2020 | Program: IA | Phase: BG-04-2014 | Award Amount: 7.40M | Year: 2015
INMARE stands for Industrial Applications of Marine Enzymes: Innovative screening and expression platforms to discover and use the functional protein diversity from the sea. It is a collaborative Innovation Action to streamline the pathways of discovery and industrial applications of new marine enzymes and bioactives for targeted production of fine chemicals, drugs and in environmental clean-up applications. The INMARE consortium will unify the multidisciplinary expertise and facilities of academic and industry partners. This will include integrating the following core activities: advanced technologies to access and sample unique marine biodiversity hot-spots; state-of-the art technologies for construction of metagenomic libraries; innovative enzyme screening assays and platforms; cutting-edge sequence annotation pipelines and bioinformatics resources; high-end activity screening technology; bioanalytical and bioprocess engineering facilities and expertise, nanoparticle-biocatalysts; high-quality protein crystallization and structural analysis facilities and experts in IP management for biotechnology. The companies involved in the project are market leaders in enzyme production and biocatalysis processes designed to efficiently deliver safer (pharmaceuticals) cheaper (agriculture) and biobased (biopolymers) products. They also have impressive track record in environmental clean-up technologies and are committed to promoting public understanding, awareness and dissemination of scientific research. The main emphasis will be focused on streamlining and shortening the pipelines for enzyme and bioactive compound discovery towards industrial applications through the establishing of marine enzyme collections with a high proportion of enzymes-allrounders. The project will also prioritize the identification of novel lead products and the delivery of improved prototypes for new biocatalytic processes.
Agency: Cordis | Branch: H2020 | Program: BBI-RIA | Phase: BBI.R10-2015 | Award Amount: 5.00M | Year: 2016
Sustainable production of chemical building blocks and other added value products from plant biomass is required for a bio-based economy. However, the biomass biorefineries should benefit not only from the use of renewable feedstocks but also from greener and more efficient bio-chemical technologies. Previous projects have shown the potential of oxidative enzymes in the production of some added value compounds from biomass components. Of special interest are still unexplored oxidation/oxyfunctionalization reactions (of sugar and lipid compounds) by microbial oxidoreductases, including new (self-sufficient) heme-thiolate peroxygenases. In this context, EnzOx2 plans to develop a 100% biochemical conversion of bio-based 5-hydroxymethylfurfural (HMF) into diformylfuran, a platform chemical, and 2,5-furandicarboxylic acid (FDCA), a plastic building-block. Oxidases (flavo and copper/radical) and peroxygenases will be used to perform the three-step oxidation of HMF to FDCA in a co-substrate and side-product free, one-pot conversion. On the other hand, highly (regio/stereo) selective hydroxylation of plant lipids (such as fatty acids, terpenes and steroids) by peroxygenases will be optimized for cost-effective production of flavours and fragrances (F&F), active pharmaceutical ingredients (APIs) and others. ENZOX2 aims to solve some main bottlenecks in these industrial processes by the use of bio-chemical tools (new/engineered enzymes and optimized biotransformations), to be later validated at the pilot/flagship scale. To attain this objective the consortium includes: i) two world leaders in industrial enzymes (Novozymes) and F&F (Firmenich); ii) two chemical SMEs producing HMF and chiral APIs (AVA-Biochem and Chiracon); iii) two specialized biotechnology SMEs (JenaBios and CLEA); iv) one technology centre in the Plastics sector (AIMPLAS); and v) three CSIC institutes and two universities (Dresden and Delft) with expertise in enzyme reactions and bioprocess implementation.
Agency: Cordis | Branch: H2020 | Program: BBI-RIA | Phase: BBI.VC3.R9-2015 | Award Amount: 4.46M | Year: 2016
MACRO CASCADE will prove the concept of the cascading marine macroalgal biorefinery i.e. a production platform that covers the whole technological chain for processing sustainable cultivated macro-algae biomass also known as seaweed - to highly processed value added products. The macro-algae biorefinery will be capable of processing multiple feedstocks, by deploying a range of mechanical, physicochemical and enzymatic pre-processing and fractionation techniques combined with chemical, enzymatic or microbial conversion refinery techniques for generation of a diversity of added-value products for industries within food, feed, cosmetics, pharmaceutical and fine chemicals. Algae based products for food, feed, cosmetics, pharmaceutical will be tested and documented for their bio-activities and health properties. The participation of two major industries and five SMEs demonstrate a significant commercial interest in the outcome MACRO CASCADE. The MACRO CASCADE approach contributes to the zero waste society as the left-over residuals from the biorefinery process can be used for fertilizers and bio-energy.
Agency: Cordis | Branch: H2020 | Program: BBI-IA-FLAG | Phase: BBI.VC1.F1 | Award Amount: 30.12M | Year: 2016
The BIOSKOH project will pave the way for a Second Generation European Circular Bioeconomy by showcasing how a number Innovation Stepping Stones can realise a breakthrough in techno-economic viability of lignocellulosic biorefineries. It will do so through a two stage investment process and development path to realise the largest (110 kton) second generation (2G) biorefinery in Europe. It starts from a brownfield industrial site in the eastern part of the Slovak Republic to realise the 1st stage Flagship plant to produce 55 kton of cellulosic ethanol per year for EU bio-fuel mandates. Partners include the full value chain starting from land owners and feedstock producers, supply chain experts and an agronomical research partner to set-up a new biomass value chain exploiting large amounts of currently unused crop residues (kton/year), and developing newly grown dedicated crops on marginal land (total circa 320 kton/year), as such revitalising the regional economy. Technology providers (Biochemtex, Novozymes and Lesaffre) developed, tested and demonstrated in the only available semi-industrial scale 2G biorefinery research plant (Crescentino), an innovative integrated pre-treatment, hydrolyses and fermentation package, with higher yield and lower CAPEX which will now be upscaled to the 1st of a kind commercial scale Flagship, to be built by Energochemica. Aim is to showcase techno-economic viability based on a sound business plan and 4 stepping stones (yield, biomass cost, brownfield and industrial symbiosis). Dedicated innovation actions by expert partners include assessing increased cascading potential through lignin valorisation and 2G bio-chemicals, LCA, Socio-economic impact analyses, business plan for a 2nd investment round, exploitation, dissemination and replication actions to various bio-economy clusters in Europe, thus giving both a short term and a long term contribution to the European Industrial Renaissance and bio-economy.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 4.07M | Year: 2016
The revolution of biotechnology has led to the creation of various types of therapeutic biologics with the potential to provide treatment for new chronic and malignant diseases. Though the potential advantages of biologics lay in their high specificity and potency combined with few side effects, their formulation still remains a large challenge to pharmaceutical scientists. This is in part due to the complex, not-well understood relationship between the physicochemical properties of proteins and formulation conditions required for protein stability. A comprehensive understanding of the molecular mechanisms behind protein stabilization and solubility would provide the formulation scientists with knowledge of the interplay between formulation and stability that in turn could potentially make formulation development faster, cheaper and less labour intensive than the currently used broad screening approach. Understanding the susceptibilities of formulations to protein aggregation and denaturation can reduce the response time to for instance product failure. Few universities in Europe have formulation of biologics as a scientific subject. Consequently, the pharmaceutical industry is forced to train scientists - a challenge for larger companies, and an insurmountable task for smaller companies. Scientists in the field of structural biology, biophysics, protein formulation and stability have formed a consortium to systematically map physicochemical properties of biologics, formulation conditions and protein stability. The main objective of the consortium is to provide a new generation of innovative and entrepreneurial early-stage researchers that will develop methodologies, tools and databases to guide the formulation of robust biologics. The consortium will not only provide an excellent platform to train a new generation of formulation scientists, but also establish avenues for designing new formulation strategies and thereby securing the leading edge of EU expertise.